Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$26.97 USD

26.97
2,911,983

-0.20 (-0.74%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $26.97 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Allergan's Anti-Infective Drug Avycaz Receives Third FDA Nod

by Zacks Equity Research

The FDA's label expansion approval for Allergan's (AGN) Avycaz marks its third therapeutic indication nod for the anti-infective drug in the United States.

    Puma, CANbridge Team Up to Commercialize Nerlynx in China

    by Zacks Equity Research

    Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.

      Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review

      by Zacks Equity Research

      Alnylam's NDA for lead candidate patisiran is accepted by the FDA and granted priority review. The FDA also set an action date of Aug 11, 2018.

        Is a Beat in the Cards for Glaxo (GSK) This Earnings Season?

        by Zacks Equity Research

        Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might lead the company to an earnings beat in Q4.

          Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings?

          by Zacks Equity Research

          Gilead's HCV franchise is under significant pressure due to increasing competition and the decline in franchise sales is expected to impact fourth-quarter results.

            Roche (RHHBY) Posts Solid 2017 Sales on Tecentriq & Alecensa

            by Zacks Equity Research

            Roche reported strong sales for 2017 buoyed by performance of new drugs ??? Tecentriq, Alecensa and Perjeta which offset the decline in Tarceva and Avastin.

              Novo Nordisk (NVO) Misses Q4 Earnings Estimates, Sales Beat

              by Zacks Equity Research

              Novo Nordisk's (NVO) top-line growth was backed by growth in new-generation insulin, Victoza, Saxenda, and haemophilia products.

                Amgen Gets CHMP Nod to Add ENDEAVOR Data on Kyprolis Label

                by Zacks Equity Research

                Amgen (AMGN) gains consent from the Committee for Medicinal Products for Human Use to add overall survival data from a phase III study on the label of its cancer drug, Kyprolis.

                  Puma & Medison Team Up to Commercialize Nerlynx in Israel

                  by Zacks Equity Research

                  Puma (PBYI) and Medison enters into a licensing deal to commercialize Puma's breast cancer treatment drug Nerlynx in Israel.

                    What's in the Cards for GW Pharma (GWPH) in Q1 Earnings?

                    by Zacks Equity Research

                    GW Pharma (GWPH) will report fiscal first-quarter results next week. Investors focus is expected to be on the Epidiolex commercialization plan.

                      Debapriya Chakraborty headshot

                      Theravance's NDA for COPD Candidate Gets FDA Acceptance

                      by Debapriya Chakraborty

                      The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018.

                        Roche Gets Breakthrough Therapy Designation For ASD Drug

                        by Zacks Equity Research

                        Roche obtains Breakthrough Therapy Designation for its experimental drug oral medicine balovaptan from the FDA which is likely to expedite the review and development of the drug.

                          Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?

                          by Zacks Equity Research

                          Vertex Pharmaceuticals (VRTX) will report its Q4 results on Jan 31, 2018.

                            Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion

                            by Zacks Equity Research

                            The Committee for Medicinal Products for Human Use passes a positive viewpoint on Glaxo's (GSK) shingles vaccine, Shingrix. A final decision from the EU is awaited in April 2018.

                              Quality Systems (QSII) Q3 Earnings in Line, Revenues Beat

                              by Zacks Equity Research

                              Quality Systems (QSII) benefits from solid bookings and acquisitions in Q3.

                                Vertex (VRTX) Stock Up 70% in a Year's Time: Here's Why

                                by Zacks Equity Research

                                Vertex Pharmaceuticals' (VRTX) stock rallies on consistent expansion in patient population through label expansions of Kalydeco and Orkambi and positive data readout from pivotal studies.

                                  Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y

                                  by Zacks Equity Research

                                  Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.

                                    Shire Gets FDA Nod for Cinryze Tech Transfer to New Site

                                    by Zacks Equity Research

                                    Shire (SHPG) receives an FDA approval for transferring the product manufacturing technology of its hereditary angioedema drug, Cinryze, to its manufacturing site in Vienna, Austria.

                                      EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down

                                      by Zacks Equity Research

                                      Puma's (PBYI) shares decline after CHMP conveyed the company that the former will probably vote against the approval of breast cancer drug Nerlynx at the CHMP meeting scheduled in February.

                                        The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ

                                        by Zacks Equity Research

                                        The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ

                                          Novartis Announces Positive Results on Migraine Candidate

                                          by Zacks Equity Research

                                          Novartis announced positive results on migraine candidate, AMG334, from the phase IIIb study. The candidate is being developed in collaboration with Amgen,

                                            Anthera's Sollpura Strong on Positive Futility in Phase III

                                            by Zacks Equity Research

                                            Anthera (ANTH) posts positive results from the second interim futility analysis of Sollpura for EPI. Top-line data from the study is expected in the first quarter of 2018.

                                              Seattle Genetics' Adcetris Gets EU Nod for Label Expansion

                                              by Zacks Equity Research

                                              European Commission extend the current conditional marketing authorization for an expanded indication of Adectris of Seattle Genetics (SGEN) and partner Takeda.

                                                Regeneron's Dupixent Receives MHLW Nod for Label Expansion

                                                by Zacks Equity Research

                                                Ministry of Health, Labor and Welfare (MHLW) in Japan has granted approval for the label expansion of Regeneron's (REGN) Dupixent.

                                                  BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall

                                                  by Zacks Equity Research

                                                  Shares of BioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) plunge following the announcement of their merger.